Pfizer Inc. (NYSE:PFE) Shares Purchased by Schwerin Boyle Capital Management Inc.

Schwerin Boyle Capital Management Inc. grew its position in shares of Pfizer Inc. (NYSE:PFE) by 0.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 719,425 shares of the biopharmaceutical company’s stock after purchasing an additional 3,700 shares during the quarter. Pfizer accounts for about 2.0% of Schwerin Boyle Capital Management Inc.’s holdings, making the stock its 17th biggest holding. Schwerin Boyle Capital Management Inc.’s holdings in Pfizer were worth $19,086,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Norges Bank bought a new position in Pfizer in the 4th quarter worth about $2,328,986,000. Charles Schwab Investment Management Inc. increased its stake in shares of Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after acquiring an additional 25,315,159 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Pfizer in the fourth quarter valued at $274,694,000. Massachusetts Financial Services Co. MA grew its stake in shares of Pfizer by 7.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares during the last quarter. Finally, APG Asset Management N.V. increased its holdings in shares of Pfizer by 1,106.0% in the fourth quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company’s stock valued at $143,967,000 after buying an additional 5,153,257 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $22.10 on Tuesday. The business’s 50-day simple moving average is $25.16 and its 200-day simple moving average is $26.33. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The firm has a market cap of $125.34 billion, a price-to-earnings ratio of 15.67, a P/E/G ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.10 earnings per share. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PFE has been the topic of a number of recent analyst reports. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Truist Financial dropped their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. The Goldman Sachs Group restated a “neutral” rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. UBS Group dropped their price objective on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 8th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.07.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.